I have continued to be successful in my research, my teaching and development as a leader in the field of myasthenia gravis. I continue to publish work that focuses on patients with myasthenia gravis and therapeutics in animal models of myasthenia gravis. I obtained a grant from the Muscular Dystrophy Association to pursue the investigation of inhibitor of apoptosis in the survival of autoreactive B cells. I have active in collaborations with pharmaceutical companies to evaluate their agents for efficacy in animal models of myasthenia gravis. In my teaching, I have continued to develop as an educator. I have mentored two students this year. In service to the myasthenia gravis community, I continue to play a leadership role as chair of the executive committee of the MG Foundation of America’s medical scientific advisory board and serve on its Research Committee. My presence as a researcher on the executive committee has brought clear initiatives to develop therapeutics specifically aimed for myasthenia gravis. I organized the speakers for the International Myasthenia Gravis and Related Disorders Conference, which occurs every five years. And in service to the George Washington University, I have participated in the University Research committee and served as a judge for Research Days..